The inclusion complex of carvacrol and ß-cyclodextrin reduces acute skeletal muscle inflammation and nociception in rats.

BACKGROUND: Skeletal muscle inflammation is strongly associated with pain and may impair regeneration and functional recovery after injury. Since anti-inflammatory and antinociceptive effects have been described for the inclusion complex of carvacrol and ß-cyclodextrin (ßCD-carvacrol), this study investigated the effects of ßCD-carvacrol in a model of acute skeletal muscle inflammation. METHODS: Muscle injury was induced in male Wistar rats by injection of 3% carrageenan in the gastrocnemius muscle. Rats were orally pretreated with saline (vehicle) or ßCD-carvacrol (20, 40, 80 and 180 mg/kg) one hour before administration of carrageenan. RESULTS: The injection of carrageenan in the gastrocnemius muscle increased tissue myeloperoxidase (MPO) activity (p < 0.001), edema (p < 0.001) and the levels of tumoral necrosis factor (TNF)-α, interleukin (IL)-1ß, IL-6, macrophage inflammatory protein (MIP-2), but not IL-10 levels. Also, it increased mechanical hyperalgesia and decreased the grip force of animals. Pretreatment with ßCD-carvacrol (80 or 160 mg/kg) significantly decreased muscle MPO activity and edema 24 h after injury in comparison to vehicle-pretreated group. Animals pretreated with ßCD-carvacrol (160 mg/kg) presented significantly lower levels of IL-1ß, IL-6 and MIP-2 and higher levels of IL-10 six hours after induction and lower levels of TNF-α and MIP-2 after 24 h when compared to the vehicle group. Pretreatment with ßCD-carvacrol also reduced mechanical hyperalgesia and limited the decrease of grip force (80 or 160 mg/kg; p < 0.001) 6 and 24 h after injury. CONCLUSION: These results show that ßCD-carvacrol reduces inflammation and nociception in a model of acute injury to skeletal muscles.

Hair in Parkinson's disease patients exhibits differences in Calcium, Iron and Zinc concentrations measured by flame atomic absorption spectrometry - FAAS.

Imbalances in metals have emerged as playing a role in the pathophysiology of Parkinson's Disease (PD). Monitoring of metal levels could serve as a biomarker of presence, or future development, of this disease. To this end, we evaluated the ability of flame atomic absorption spectrometry (FAAS) to assess the concentrations of Ca, Fe and Zn in hair of PD patients and to investigate if there was an association with age and disease duration. Hair samples were collected from 26 clinically-diagnosed PD patients, and 33 healthy individuals. Concentrations of Ca and Fe were lower in PD patients when compared to control, whereas, a higher concentration of Zn was detected in PD patients. Levels of Ca and Fe did not vary with age nor with the duration of PD. While Zn did not present variation with duration of the disease, there was a correlation with age as PD patients older than 65 years exhibited a higher concentration of Zn than controls. We conclude that FAAS is useful for detecting differences in Fe, Ca and Zn in hair samples of patients with PD. Hair samples required for this method are easy to collect, and the technique relies on a simple method of digestion of the organic matrix. The ease of use of FAAS should allow for more frequent monitoring of metallic levels in patients in a variety of small clinical situations, thereby offering the hope of allowing systematic tracking of metal levels as the disease progresses, or prior to the defining motor symptoms.